MedTrace Logo

Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements

NCT05037357 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 370

Last updated 2022-07-06

No results posted yet for this study

Summary

Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a qualified laboratory in Southern China, the highest endemic area of NPC. Passing-Bablok regression and difference plots will be used to compare results from each center to the all-method median and mean values. Agreement among methods will be evaluated against bias derived from a biological variation.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DIAGNOSTIC_TEST

Plasma EBV DNA qPCR test

Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.

Sponsors & Collaborators

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Zhongshan People's Hospital, Guangdong, China

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ming-Yuan Chen, MD, PhD · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037357 on ClinicalTrials.gov